Novo Nordisk A/S (NVO)

36.05
1.08 3.09
NYSE : Health Care
Prev Close 34.97
Open 35.22
Day Low/High 35.18 / 36.10
52 Wk Low/High 30.89 / 59.00
Volume 3.96M
Avg Volume 4.50M
Exchange NYSE
Shares Outstanding 2.60B
Market Cap 91.52B
EPS 2.00
Div & Yield 0.91 (2.60%)

Latest News

Novo Nordisk Is an Opportunity

Novo Nordisk Is an Opportunity

I bought the stock too early, but I am adding more.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, CECE, EMN, FC, NNI, PDCO, SAH, SAMG, WERN Downgrades: ATW, CERN, IPXL, NVO, OMCL, PHII, PHIIK, PLKI, SVT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

One World Trade Center To Glow Blue In Honor Of World Diabetes Day Tonight

One World Trade Center To Glow Blue In Honor Of World Diabetes Day Tonight

The American Diabetes Association, JDRF, The New York Stem Cell Foundation Research Institute and Novo Nordisk Inc. Unite in the Battle Against Diabetes

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.

NKE, AGN, NFLX: Jim Cramer's Views

NKE, AGN, NFLX: Jim Cramer's Views

Cramer shares his views on price war victims. Nike, Allergan and Netflix are among the stocks discussed.

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.

ZBH's Big Unjustified Price Correction

ZBH's Big Unjustified Price Correction

Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.

Cramer: How Bad Was Today? Let Us Count the Ways

Cramer: How Bad Was Today? Let Us Count the Ways

Today there was a virtual vacuum of good news in the stock market.

Cramer: With the Election Coming, Valeant's Problem Is Increasing

Cramer: With the Election Coming, Valeant's Problem Is Increasing

We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

In a "take no pain, take no prisoners" market, health care stocks languish.

European Stocks Mixed on Divergence in Economic Data, Mixed Earnings

European Stocks Mixed on Divergence in Economic Data, Mixed Earnings

Economic data in France disappoints; Germany and U.K. beat expectations.

Novo Nordisk Stock Plunges as U.S. Problems Cloud Outlook

Novo Nordisk Stock Plunges as U.S. Problems Cloud Outlook

The Danish drugs maker halves targets for operating profit growth.

European Stocks Slip After French GDP Miss; Novo Nordisk Plunges on U.S. Woes

European Stocks Slip After French GDP Miss; Novo Nordisk Plunges on U.S. Woes

Pharma group Sanofi rises on improved guidance and RBS gains after a third-quarter profit beat.

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

European Week Ahead: GDP Data, Consumer Poll to Measure Brexit Damage

Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.

Roche Avastin Shortfall Pushes Quarterly Sales Below Forecasts

Roche Avastin Shortfall Pushes Quarterly Sales Below Forecasts

Shares in the stock decline only marginally as the pharmaceuticals group sticks with its full-year forecast.

'Left-to-Right' Makes Might

'Left-to-Right' Makes Might

Profiting from these companies' steady long-term gains requires patience.

Novo Nordisk (NVO) Stock Drops, Explores Inventing New Forms of Insulin

Novo Nordisk (NVO) Stock Drops, Explores Inventing New Forms of Insulin

Novo Nordisk (NVO) is developing new types of insulin, such as a pill-based form, in response to growing competitive pressures.

Novo Nordisk: Growth at a Good Price

Novo Nordisk: Growth at a Good Price

Novo is 'not yet screamingly cheap, but it is certainly approaching great value.'

Here's Why Shares of Novo Nordisk are Lower Thursday

Here's Why Shares of Novo Nordisk are Lower Thursday

Shares of Novo Nordisk were lower Thursday after announcing layoffs across its global business.

Novo Nordisk Takes Axe to Workforce as Growth Falters

Novo Nordisk Takes Axe to Workforce as Growth Falters

The Danish pharmaceuticals maker is facing tighter margins and tougher competition in the U.S.

European Stocks Rise; Oil Producers Cheer OPEC Deal, Deutsche Bank Recovers

European Stocks Rise; Oil Producers Cheer OPEC Deal, Deutsche Bank Recovers

Energy stocks rise even as oil prices give up initial gains.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Trading Beats Buy and Hold: An Illustration

Trading Beats Buy and Hold: An Illustration

The ability to exit pricey shares with the chance to buy them back cheaper occurs with regularity.